Clinical Phenotypes of COPD Patients Between in Plateau and Plain

Clinical and Radiological Phenotypes of Patients With Stable COPD Between in Plateau and Plain

We aimed to collect clinical and radiological data of patients with stable COPD in plateau and plain, and compare the clinical phenotypic characteristics and imaging features of COPD patients in these two areas.

Study Overview

• Status: Completed
• Conditions: Pulmonary Disease, Chronic Obstructive
• Intervention / Treatment: Other: No intervention

Detailed Description

The purpose of this study was to investigate the clinical phenotypic characteristics and imaging features of patients with stable chronic obstructive pulmonary disease (COPD) in plateau and plain. We conducted a cross-sectional study, collecting clinical data of stable patients in plateau and plain, and comparing the clinical phenotypic characteristics and imaging features of COPD patients in these two areas.

• Study Type: Observational
• Enrollment (Actual): 104

Contacts and Locations

• Study Contact: Name: Yongchang Sun, M.D.; Phone Number: 86-15611963697; Email: suny@bjmu.edu.cn

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100191
      • Peking University Third Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

We consecutively enrolled patients with COPD from January 2018 to December 2021, who visited the outpatient of Department of Respiratory Medicine in Peking University Third Hospital or Tibet Autonomous Region People's Hospital.

Description

Inclusion Criteria:

• meeting the diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and had definite airflow limitation with a post-bronchodilator forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC)<0.7.

Exclusion Criteria:

• age <40 years;
• subjects with airway diseases other than COPD;
• acute exacerbation of COPD in the past 3 months;
• active tuberculosis;
• cardiovascular or cerebrovascular events in the past 3 months;
• cognitive dysfunction such as vascular dementia or Alzheimer's disease;
• refusal to participate in this study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
COPD patients in the plateau; We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to December 2021.	Other: No intervention; No intervention
COPD patients in the plain; We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Peking University Third Hospital from January 2018 to December 2021.	Other: No intervention; No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of respiratory symptoms	COPD Assessment Test	Data were obtained during the interview.
Exacerbation	Frequency of exacerbations in the past year	Data were obtained during the interview.
Spirometry testing	FEV1 %predicted, FVC %predicted, ratio of FEV1/FVC	Data were obtained during the interview.
Emphysema	The percentage of the LAA divided by total lung volumes (LAA%) was used as an index of the severity of emphysema in quantitative CT examination.	Within 3 months of the interview.
Airway remodeling -1	Bronchial wall thickness (WT, mm) was used as one of the measurements for assessment of airway remodeling in quantitative CT examination.	Within 3 months of the interview.
Airway remodeling -2	Luminal area (LA, mm2) was used as one of the measurements for assessment of airway remodeling in quantitative CT examination.	Within 3 months of the interview.
Airway remodeling -3	Bronchial wall area (WA, mm2) was used as one of the measurements for assessment of airway remodeling in quantitative CT examination.	Within 3 months of the interview.

Collaborators and Investigators

• Sponsor: Peking University Third Hospital
• Collaborators: Tibet Autonomous Region People's Hospital
• Investigators: Principal Investigator: Yongchang Sun, M.D., Peking University Third Hospital

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2020
• Primary Completion (Actual): December 31, 2021
• Study Completion (Actual): December 31, 2021

Study Registration Dates

• First Submitted: June 29, 2021
• First Submitted That Met QC Criteria: July 7, 2021
• First Posted (Actual): July 15, 2021

Study Record Updates

• Last Update Posted (Estimated): November 17, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Lung Diseases, Obstructive; Chronic Disease; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: LM2020390

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No